Yurie Katsube

Yurie Katsube

Auto-generated profile, based on publicly available information

Yurie Katsube

Department of Clinical Pharmacology and Therapeutics Kyoto University Hospital Kyoto Japan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
YKYoshiki Katada
Yoshiki Katada
DHDaiki Hira
Daiki Hira
KUKeisuke Umemura
Keisuke Umemura
YKYurie Katsube
Yurie Katsube
HIHiroki Ishimura
Hiroki Ishimura
TTTomohiro Terada
Tomohiro Terada
Voriconazole (VRCZ) is a triazole antifungal agent with a broad antifungal spectrum. It is metabolized by hepatic cytochrome P450 (CYP) isozyme CYP2C19, whose genetic polymorphism causes significant variability in drug efficacy and safety. Poor metabolizer alleles of CYP2C19 are more common in Asian populations, increasing the risk of supratherapeutic VRCZ levels. We have developed a novel nomogram based on CYP2C19 genetic polymorphisms. This study aimed to evaluate whether CYP2C19 genotype‐guided VRCZ therapy reduces toxicity in Japanese patients. This retrospective study included 64 patients (genotype‐guided group, n = 26; comparison group, n = 38). The primary outcome was defined as the composite incidence of adverse events commonly observed with VRCZ, represented by the combined occurrence of grade ≥ 2 hepatotoxicity and visual symptoms. Secondary outcomes included the proportion of patients maintaining VRCZ trough concentrations within the therapeutic range (1–4 μg/mL) and the treatment response at 28 days. The composite incidence of adverse events was significantly lower in the genotype‐guided group than in the comparison group (p = 0.003). VRCZ discontinuation due to adverse events occurred in nine patients (23.7%) in the comparison group and one (3.8%) in the genotype‐guided group (p = 0.039). More patients in the genotype‐guided group were achieved through concentrations within the therapeutic range at the initial sampling point. However, treatment response rates did not differ significantly between the groups. VRCZ administration based on CYP2C19 genotyping improved therapeutic trough levels management and reduced adverse effects while maintaining therapeutic efficacy. These findings highlight the importance of CYP2C19 genotyping for VRCZ treatment in Japanese patients.

1 August 2024 in Kidney360
Verified
Journal Article
Open access
CYChinami Yamawaki
Chinami Yamawaki
SNShunsaku Nakagawa
Shunsaku Nakagawa
KIKeiko Ikuta
Keiko Ikuta
YKYurie Katsube
Yurie Katsube
NINatsuki Imayoshi
Natsuki Imayoshi
TTTomohiro Terada
Tomohiro Terada
Key Points: This is the first study to use a large database of patients with cancer to examine the association between the studied drugs and AKI. The use of either proton pump inhibitors or immune checkpoint inhibitors was associated with an increased risk of AKI. However, their additive interaction was not identified. Background: An association between proton pump inhibitor (PPI) use and an increased risk of AKI has been confirmed. This study aimed to evaluate the effects of PPI use on the risk of AKI in patients with cancer who were administered immune checkpoint inhibitors (ICIs), a class of drugs used in cancer treatment, and in those who were not. Methods: We used a database provided by the Health, Clinic, and Education Information Evaluation Institute, which included demographic data, diagnoses, prescriptions, and laboratory results. We conducted a nested case–control study of 38,930 patients with cancer who were new PPI or ICI users and had no history of AKI before cohort entry. The odds ratio (OR) for AKI was estimated using conditional logistic regression models. Results: During a mean follow-up of 8.3 months, 5870 cases of AKI were identified (incidence rate, 21.9/100 person-years). Compared with never or past PPI use without ICI use, the adjusted ORs of AKI for current PPI use without ICI use, past or never PPI use with prior ICI use, current PPI use with prior ICI use were 2.20 (95% confidence interval [CI], 2.01 to 2.40), 1.72 (95% CI, 1.37 to 2.17), or 2.62 (95% CI, 1.75 to 3.93), respectively. The risk of AKI in patients treated with both PPIs and ICIs was not higher than the additional or multiplication of the risks in those who were treated with PPIs or ICIs alone. Conclusions: This study reinforces the association between PPI and ICI use and the increased risk of AKI. Although the interaction between the two drug classes was not detected, these findings highlight the need for careful monitoring and evaluation of kidney function in patients treated with PPIs and ICIs.

18 September 2025 in Transplant Infectious Disease
Verified
Journal Article
Open access
YKYurie Katsube
Yurie Katsube
KUKeisuke Umemura
Keisuke Umemura
YUYuzuki Urabe
Yuzuki Urabe
MOMiori Ono
Miori Ono
YKYoshiki Katada
Yoshiki Katada
TTTomohiro Terada
Tomohiro Terada
Background: Valganciclovir (VGCV) prophylaxis effectively prevents cytomegalovirus infection in lung transplant patients. However, VGCV‐induced neutropenia causes early cessation. Nucleoside diphosphate‐linked moiety X‐type motif (NUDT) 15 degrades the ganciclovir (GCV) triphosphate, an active metabolite. We assessed the effects of NUDT15 variants on neutropenia and VGCV cessation in recipients of lung transplants. Methods: We recruited 28 patients who had received lung transplants and VGCV prophylaxis and genotyped NUDT15 exons 1–3 using Sanger sequencing. Neutrophil counts were monitored from 1 month to 1 year in the wild‐type and NUDT15 reduced‐function variant groups. Cumulative incidences of neutropenia (< 1500/mm 3 ) and neutropenia‐related cessation within 1 year, including late‐onset neutropenia, were assessed using Kaplan–Meier analysis. A subgroup analysis was conducted focusing on patients with stable renal function, the primary route of excretion for GCV. Results: Of the 28 patients, nine carried NUDT15 variants (Arg139Cys, Val18Ile, Val18_Val19insGlyVal, Arg139Cys/Val18Ile). The neutrophil count nadir within 1 month of treatment was lower in the NUDT15‐variant group than in the wild‐type group. A higher incidence of neutropenia and VGCV cessation was observed in the NUDT15‐variant group, but without statistical significance. Among 13 patients with stable renal function, all four in the NUDT15‐variant group developed neutropenia and cessation within 60 days, compared with two of nine in the wild‐type group. Covariance analysis showed that NUDT15 variants were associated with decreased neutrophil counts, independent of GCV trough concentration. Conclusion: NUDT15 variants increase the risk of early neutropenia during VGCV prophylaxis in lung transplant recipients.

2 June 2025 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YKYusuke Kojima
Yusuke Kojima
YKYoshiki Katada
Yoshiki Katada
SNShunsaku Nakagawa
Shunsaku Nakagawa
KUKeisuke Umemura
Keisuke Umemura
YKYurie Katsube
Yurie Katsube
TTTomohiro Terada
Tomohiro Terada

25 March 2025 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KUKeisuke Umemura
Keisuke Umemura
YKYoshiki Katada
Yoshiki Katada
YKYurie Katsube
Yurie Katsube
DHDaiki Hira
Daiki Hira
MTMasahiro Tsuda
Masahiro Tsuda
TTTomohiro Terada
Tomohiro Terada